Three clinical trials presented at the American Heart Association’s Scientific Sessions 2026 examine post-stroke care strategies, testing the diuretic spironolactone, the FXIa inhibitor asundexian, and intensive blood pressure targets to protect high-risk cardiovascular patients.
In Plain English: The Clinical Takeaway
- Early Diuretic Intervention: Adding spironolactone (a medication that helps the body remove excess salt and water) soon after a stroke safely lowers blood pressure and helps more patients hit guideline-recommended goals.
- Kidney Monitoring: Intensive blood pressure control provides heart protection but requires close supervision of renal function due to a higher risk of kidney-related events.
High blood pressure remains a primary modifiable risk factor for stroke, yet post-stroke management often falls short of clinical targets. Addressing this gap, the REDUCE trial tested adding the inexpensive diuretic spironolactone to the regimens of adult stroke survivors with uncontrolled hypertension. Spironolactone is traditionally reserved for late-stage treatment when three other medications fail, but investigators evaluated its use immediately following a stroke.
The trial enrolled 160 adult stroke survivors across five U.S. medical centers, featuring participants with an average age of 63, where 38% were women, roughly 30% self-identified as Black adults, and 16% as Hispanic adults. Patients in the trial were receiving only two antihypertensive medications at baseline. Following home blood pressure monitoring, participants were randomized to daily spironolactone or standard post-stroke care.
Dr. Jordana Cohen and Dr. C. Michael Gibson discuss the REDUCE trial: Spironolactone significantly reduced home systolic blood pressure at 3 months post-stroke, offering a vital therapeutic strategy to address suboptimal blood pressure control after cerebrovascular events.… pic.twitter.com/6lRkq3ft9k
At three months, patients taking spironolactone recorded home-measured systolic blood pressure approximately 8 mm Hg lower than the standard care group, averaging ~126 mm Hg versus 133 mm Hg. Diastolic blood pressure (the bottom number) dropped by about 4 mm Hg on average in the spironolactone arm. 52% of patients receiving the diuretic reached the guideline-recommended goal of under 130/80 mm hg, compared to 30% in the standard care group.
“We were surprised to see that BP dropped twice as much as we expected. In an exploratory analysis, the BP drop was larger in people who started this medication within three months after a stroke,” Jordana B. Cohen, MD, stated while presenting the findings. She noted that the trial was not powered to determine whether spironolactone prevents subsequent strokes or myocardial infarctions, leaving that question for larger, longer studies.
🧠 REDUCE: 160 stroke survivors; 38% women Adding spironolactone vs usual care: home significantly ⤵️ SBP ~126 vs 133 mmHg at 3mo ✅ Promising BP strategy ⚠️ Fewer recurrent strokes NOT established ⚠️ 👀 potassium#AHA26 #ScientificSessions26 #CVPrev #Ilovespironolactone pic.twitter.com/gZVdBfg0Av
Intensive Targets Reduce Cardiovascular Events
Conducted across 30 health centers in Brazil and simultaneously published in the New England Journal of Medicine, the trial enrolled nearly 4,500 patients with a history of ischemic stroke or transient ischemic attack (TIA).
Participants with a mean age of 64 were randomized to intensive therapy targeting a systolic blood pressure below 120 mm Hg or standard therapy targeting below 140 mm Hg.
Over a median follow-up of nearly four years, the intensive-treatment group achieved a mean systolic blood pressure of 122.0 mm Hg, compared to 135.2 mm Hg in the standard-treatment group. Primary outcome events occurred in 10.9% of the intensive group versus 13.5% of those receiving standard care, representing a 21% reduction in major cardiovascular events.
Otavio Berwanger, M.D., Ph.D., chair of the OPTIMAL study Steering Committee, emphasized that controlling blood pressure after a stroke helps prevent secondary vascular events and protects patients’ lives. However, investigators observed a trade-off. A sustained reduction of 50% or more in the estimated glomerular filtration rate or progression to end-stage renal disease occurred more frequently in the intensive treatment group.
“We emphasize that achieving lower blood pressure safely requires appropriate medical supervision and additional monitoring, particularly of kidney function,” stated principal investigator Gisele Sampaio, M.D., Ph.D., M.Sc., professor of neurology at the Federal University of São Paulo.
In a separate presentation at the meeting, researchers in the OCEANIC-STROKE trial also evaluated FXIa inhibition with asundexian in non-cardioembolic stroke or high-risk TIA patients, finding that asundexian reduced ischemic stroke rates with bleeding profiles comparable to placebo across all Framingham Risk Score categories.
🧠 OPTIMAL-Stroke: 4,368 prior ischemic stroke/TIA; 47.9% women, followed for 3.9y 🫀lower 🆚 higher BP: SBP <120 vs <140: MACE 10.9% vs 13.5%; HR 0.79 (95% CI 0.67–0.94) 💥Supports lower target BPhttps://t.co/w7gGY7FIrD#AHA26 #ScientificSessions26 #CVPrev @NEJM pic.twitter.com/KBrVPlHYI3
| Clinical Trial | Intervention / Target | Primary Population | Key Finding |
|---|---|---|---|
| REDUCE | Spironolactone addition | 160 stroke survivors with uncontrolled hypertension | Systolic BP lowered by ~8 mm Hg at 3 months vs. standard care |
| OPTIMAL-Stroke | Intensive BP target (<120 mm Hg) | ~4,500 adults with prior ischemic stroke or TIA | 21% reduction in major cardiovascular events over ~4 years |
| OCEANIC-STROKE | Asundexian (FXIa inhibitor) | Non-cardioembolic stroke / high-risk TIA | Reduced ischemic stroke with bleeding similar to placebo |
Risk of Hyperkalemia and Kidney Events with Intensive Control
Spironolactone blocks aldosterone, a hormone that instructs the kidneys to retain sodium and water while excreting potassium, which can lead to hyperkalemia (dangerously high blood potassium levels) if renal function is impaired. Similarly, intensive blood pressure targets below 120 mm Hg demonstrated an increased incidence of kidney-related adverse events in clinical evaluation.
Patients with pre-existing advanced chronic kidney disease, severe electrolyte imbalances, or known hypersensitivity to trial medications must avoid unmonitored medication adjustments. Stroke survivors should consult a neurologist, cardiologist, or primary care physician before altering doses or adding new antihypertensive agents.
Immediate medical attention is warranted if patients experience symptoms of acute kidney injury—such as sudden changes in urination, severe fatigue, or confusion—or acute neurological deficits suggestive of recurrent stroke.
REDUCE trial: Spironolactone-based blood pressure management achieved clinically important and durable reductions in home systolic blood pressure at 3 months compared with standard care in patients with prior stroke. Download slides here: https://t.co/lNChGFawoP pic.twitter.com/1joqLwWf3L
References
- American Heart Association Scientific Sessions 2026 Late-Breaking Science Abstracts (REDUCE, OCEANIC-STROKE, OPTIMAL-Stroke).
- New England Journal of Medicine: Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke.
- New England Journal of Medicine: Related trial publications and glycemic/cardiovascular targets.
